Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial

BACKGROUND: Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve progressive inflammation due to COVID-19. AIM OF THE STUDY: To evaluate the therapeutic effects of Tranilast in combination with antiviral drugs in non-ICU-admitted hospitalized patients with COVID-19. METHODS: This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeedi-Boroujeni, Ali, Nashibi, Roohangiz, Ghadiri, Ata A., Nakajima, Motowo, Salmanzadeh, Shokrollah, Mahmoudian-Sani, Mohammad-Reza, Hanafi, Mohammad Ghasem, Sharhani, Asaad, Khodadadi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919799/
https://www.ncbi.nlm.nih.gov/pubmed/35339280
http://dx.doi.org/10.1016/j.arcmed.2022.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919799/
https://www.ncbi.nlm.nih.gov/pubmed/35339280
http://dx.doi.org/10.1016/j.arcmed.2022.03.002

Ejemplares similares